Navigation Links
ViroPharma To Participate In Two May Healthcare Investor Conferences
Date:5/9/2013

EXTON, Pa., May 9, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Robert Doody , director of investor relations, will present at the 2013 Bank of America Merrill Lynch Healthcare Conference at 11:20 AM PT (2:20 PM ET) on Tuesday, May 14, 2013.  The conference is being held at the Encore at the Wynn Hotel in Las Vegas, NV.

ViroPharma also announced that Charles Rowland , vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 38th Annual Healthcare Conference at 9:20 AM ET on Wednesday, May 29, 2013.  The conference is being held at the Westin Boston Waterfront Hotel.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Participate in Two December Healthcare Investor Conferences
2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
3. ViroPharma Announces First Quarter 2013 Financial Results
4. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
5. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
6. Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
7. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
8. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
9. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
10. AVANIR Pharmaceuticals To participate in two conferences in March
11. P&P Optica Invited to Cambridge Innovation Centre for the Canadian Technology Accelerator Program, One of Eight Canadian Life Science Companies Chosen to Participate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today ... research program with Emerald Logic, a leader ... Technology (FACET), Emerald Logic analyzed Resverlogix,s complete ... each of 798 patients who participated in ... SUSTAIN and ASSURE. The objective of this ...
(Date:3/4/2015)... Irvine, CA (PRWEB) March 04, 2015 ... research leader in Personalized Medicine, is excited to ... “Incorporating Genetic Testing to Optimize the Management of ... be available at Medscape.com for the next year. ... medical professionals how to recognize inadequate pain treatments, ...
(Date:3/4/2015)... , March 4, 2015  BioClinica®, ... and technology provider, today announced that clinical ... countries convened at its annual European User ... to discuss the use of its ... BioClinica,s eClinical technologies include: the Microsoft Office-Smart ...
(Date:3/4/2015)... March 04, 2015 Follow us ... one of the fastest growing technologies in the life ... subcellular visualization is driving growth in nucleic acid detection ... understanding of gene expressions will continue to benefit the ... in fields ranging from pharma, biotech, food & beverage ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... YORK, Nov. 11, 2010 Oligomerix, Inc. today announced ... (SBIR) Phase II grant for $1.6M from the National ... a program to discover small molecules and antibodies targeting ... therapeutics for Alzheimer,s disease. Compound libraries will be screened ...
... 2010 StemCyte, Inc., one of the world,s preeminent ... proud to announce that the Company has been awarded ... Revenue Service,s Qualifying Therapeutic Discovery Project (QTDP) program designed ... 250 employees. The Patient Protection and Affordable ...
... Nov. 11, 2010 Wound Management Technologies, Inc., (OTC ... advanced wound care solutions, announced today that its President, ... widely-acclaimed wound care product, CellerateRX®, recent strategic developments, and ... Investors Conference to be held at the JW Marriott ...
Cached Biology Technology:Oligomerix, Inc. Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimer's Disease 2StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP) 2Wound Management Technologies to Present at LifeTech Capital Miami Medical Investors Conference 2
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ... A Global Market Overview" report to their offering. ... to ensure that an individual is who she/he is claiming ... use of a person,s unique physical characteristics, such as fingerprint, ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... the game was designed to make a lefty the ... Douglas Professor of Engineering at Washington University in St. ... mechanical engineer who specializes in aircraft and helicopter engineering ... Pastime. First of all, some numbers. "Ninety percent of ...
... from UC San Diego are collaborating with scientists ... to map patterns of biodiversity and land use ... combined with climate models, will project how climate ... policy for setting aside conservation easements. Wildlife, ...
... interview with a researcher, please contact the Communications and External ... For more information on ORNL and its research and development ... you have a general media-related question or comment, you can ... ENERGY -- Spent fuel pellets . . . ...
Cached Biology News:Baseball diamonds: the lefthander's best friend 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 3Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3
... Super Sensitive MultiLink IHC Detection ... secondary antibodies, labeled with multiple ... the bound primary antibody, and ... Streptavidin-Enzyme conjugate. This kit is ...
Sf21 Insect Cells (Live) in Max-XP Medium...
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
... unit is an inexpensive personal or mini thermal ... process. Lightweight, with a small footprint, it can ... the researcher's desk. , The Gene Cycler thermal ... not have access to a large laboratory thermal ...
Biology Products: